GlassScriptPhysician profile
David J Gooding
NPI 1053377010
$1,564.42
in general payments reported to CMS, 2019-2025
24 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.96 · 2020: $313 · 2021: $52.13 · 2022: $597 · 2023: $87.93 · 2024: $238 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $385.71 | 2022 | |
| Amgen INC. | $180.73 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $175.95 | 2020-2025 | |
| Boston Scientific Corporation | $138.06 | 2020-2025 | Watchman Flx, Watchman Access System |
| Novo Nordisk INC | $114.03 | 2020-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $83.49 | 2019-2022 | |
| Esperion Therapeutics, INC. | $71.28 | 2021-2022 | |
| Amarin Pharma, INC. | $53.38 | 2019-2020 | |
| Glaxosmithkline, LLC. | $48.12 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $38.56 | 2024-2025 | Airsupra |
| Genentech USA, INC. | $29.33 | 2020 | |
| Novartis Pharmaceuticals Corporation | $29.13 | 2022-2024 | |
| Lilly USA, LLC | $26.93 | 2020-2023 | Mounjaro |
| Abiomed | $23.26 | 2023 | Impella |
| Corcept Therapeutics | $23.05 | 2024 | Korlym |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.36 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.94 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.60 | 2024 | Rexulti |
| Ge Healthcare | $16.30 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.02 | 2022 | |
| Ibsa Pharma INC. | $14.94 | 2020 | |
| Nevro Corp. | $12.55 | 2019 | |
| Eisai INC. | $12.44 | 2020 | |
| Radius Health, INC. | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gooding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.